Efficacy of chlorofluorocarbon-free beclomethasone dipropionate 400 μg day-1 delivered as an extrafine aerosol in adults with moderate asthma

Respiratory Medicine

Volumn 92, Issue SUPPL. A, 1998, Pages 17-22

  Matthys, H ^a   Nowak, D ^b   Hader, S ^c   Kunkel, G ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c 3M Deutschland GmbH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT;

ADULT; AEROSOL; AGED; ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VITAL CAPACITY;

EID: 0031903459     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90213-X     Document Type: Conference Paper

References (13)

1. Hayman G. Why the environment matters. Br J Clin Pract 1995; Suppl. 79: 2-6.
2. June D, Schultz D. Improved performance characteristics of CFC-free aerosol MDIs. J Aerosol Med 1995; 8: 93 (abstract P97).
3. Leach C. Enhanced drug delivery through reformulation MDIs with HFApropellants. Drug deposition and its effect on preclinical and clinical programs. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V Proceedings. Interpharm Press, Buffalo Grove, IL, 1996, pp. 133-144.
4. Harrison LI, Dahl DR, Cline A et al. Pharmacokinetics and dose proportionality of beclomethasone from three strengths of a CFC-free beclomethasone dipropionate metered-dose inhaler. Biopharm Drug Dispos 1997; 18: 635-643.
5. National Heart, Lung, and Blood Institute, National Institutes of Health. Global Initiative for Asthma: global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. NIH publication 95-3659, January 1995.
6. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert Panel Report II, February 1997.
7. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680.
8. Schuirmann DJ. Design of bioavailability/bioequivalence studies. Drug Inf J 1990; 24: 315-333.
9. Malfitan VA. Beclomethasone dipropionate aerosol in the treatment of asthma in steroid-independent adults. Clin Ther 1982; 4: 472-479.
10. Lorentzon S, Boe J, Eriksson G, Persson G. Use of inhaled corticosteroids in patients with mild asthma. Thorax 1990; 45: 733-735.
11. Leblanc PL, Mink S, Keistinen T, Saarelainen PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma. Allergy 1994; 49: 817-823.
12. Davies RJ, Stampone P, O'Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92 (Suppl. A): 23-31.
13. Geddes DM. Inhaled corticosteroids: benefits and risks. Thorax 1992; 47: 404-407.